Loading...
OTCMIPIX
Market cap51kUSD
Dec 24, Last price  
0.00USD
1D
0.00%
1Q
-66.67%
Jan 2017
-99.99%
IPO
-99.95%
Name

Innovation Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:IPIX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
167.31%
Shrs. gr., 5y
28.47%
Rev. gr., 5y
%
Revenues
0k
-100.00%
000000733,4380000000423,000018,0000
Net income
-3m
L-55.76%
-34,122-47,161-510,193-1,485,331-3,433,400-5,938,297-4,894,402-3,224,482-8,247,000-13,145,000-12,852,000-15,536,000-16,362,000-9,071,000-7,010,000-18,729,000-7,161,000-3,168,000
CFO
-2m
L-66.46%
-622-5,911-80,500-211,480-1,109,293-735,703-693,859-1,907,490-7,510,000-13,071,000-9,887,000-11,711,000-13,278,000-6,332,000-4,156,000-9,495,000-6,280,000-2,106,000

Profile

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
URL
http://www.ipharminc.com/
IPO date
Apr 02, 2007
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
18
 
Cost of revenue
2,431
7,187
Unusual Expense (Income)
NOPBT
(2,431)
(7,169)
NOPBT Margin
Operating Taxes
120
Tax Rate
NOPAT
(2,431)
(7,289)
Net income
(3,168)
-55.76%
(7,161)
-61.77%
Dividends
(86)
Dividend yield
0.85%
Proceeds from repurchase of equity
5,006
BB yield
-32.05%
Debt
Debt current
268
447
Long-term debt
512
307
Deferred revenue
Other long-term liabilities
786
Net debt
(4,544)
(7,031)
Cash flow
Cash from operating activities
(2,106)
(6,280)
CAPEX
(60)
(80)
Cash from investing activities
(60)
(4,080)
Cash from financing activities
(123)
3,973
FCF
132
(6,880)
Balance
Cash
1,518
3,807
Long term investments
3,806
3,978
Excess cash
5,324
7,784
Stockholders' equity
(125,273)
(122,044)
Invested Capital
128,037
127,914
ROIC
ROCE
EV
Common stock shares outstanding
505,767
503,867
Price
0.02
-35.48%
0.03
-85.61%
Market cap
10,115
-35.24%
15,620
-81.23%
EV
5,571
8,651
EBITDA
(2,058)
(6,787)
EV/EBITDA
Interest
57
115
Interest/NOPBT